Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessionel12n31aeoq6poemklaguvg8hjg3c7gc): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the management of vitiligo is still challenging. As vitiligo is a chronic disease limited to the skin, topical rather than systemic therapies may be preferable (especially among patients with localised lesions) to avoid the long-term side-effects of the latter. A topical formulation of ruxolitinib, a selective JAK1/2 inhibitor, has recently been approved in the United States for the treatment of non-segmental vitiligo in patients aged >12 years based on data from the phase III TRuE-V1 and TRuE-V2 clinical trials. The aim of this review is to describe the current evidence concerning the efficacy and safety of topical ruxolitinib in the treatment of vitiligo, and discuss issues regarding its use in younger children and pregnant or breastfeeding women, as well as the duration and durability of treatment. The promising results obtained so far suggest that 1.5% ruxolitinib cream is an effective means of treating vitiligo.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jdv.19162 | DOI Listing |
J Am Acad Dermatol
March 2025
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Division of Dermatology, McMaster University, Hamilton, ON, Canada. Electronic address:
J Pediatr Hematol Oncol
March 2025
Department of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN.
Atopic dermatitis (AD)-like graft-versus-host disease (GVHD) is a chronic form of skin GVHD with features that include erythema, xerosis, scaling, and pruritus. Patients often require treatment with systemic immunosuppression and aggressive topical therapies for relief. Long-term effects of chronic immunosuppression are undesirable and alternative therapies are needed.
View Article and Find Full Text PDFAnn Dermatol Venereol
March 2025
Centre of Evidence of the French Society of Dermatology, Paris, France; Montpellier University, Montpellier, France. Electronic address:
Background: Vitiligo, a prevalent depigmenting condition, affects both adults and children, significantly impacting their quality of life. The standard treatment approach involves the application of topical corticosteroids in conjunction with narrow-band ultraviolet B (UVB) phototherapy. A novel topical treatment, ruxolitinib (a Janus kinase inhibitor), has recently received approval.
View Article and Find Full Text PDFRinsho Ketsueki
March 2025
Department of Hematology, Tokyo Medical and Dental University Hospital.
A 41-year-old woman with myelodysplastic syndrome underwent unrelated bone marrow transplantation following conditioning with fludarabine, busulfan, total body irradiation, and anti-thymocyte globulin. She received tacrolimus and short-term methotrexate for graft-versus-host disease (GVHD) prophylaxis. After engraftment, she developed acute GVHD involving the skin, gut, and liver.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
March 2025
Department of Dermatology, CHU de Bordeaux, National Reference Center for Rare Skin Disorders, Bordeaux, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!